In a couple of months, the first test to verify if embryonic stem cells directly injected inside patients’ brain plagued by stroke can regenerate damaged areas, will start in Scotland.
A team from Southern General Hospital of Glasgow selected 4 groups of 3 patients that will be treated during the next 2 years.
Firstly patients will take a dose of 2 millions embryonic stem cells. The amount will be gradually increased to 20 millions of stem cells, which is what doctors think patients need to start the re-creating processes.
Research on Stem Cell Treatments Abroad
If you have done any research on stem cell treatments abroad, you will undoubtedly read negative articles like this one on CNN from the mainstream media saying these companies are promising cures and are preying on the desperate, that these companies are selling “snake oil” Nothing could […]
Drug Companies and FDA Trying to Slow Adult Stem Cell Progress
In a startling new interview on stem cell research and adult stem cells in the near future, Dr. Christopher Centeno warns that Big Pharma and the FDA are teaming to control the use of a person’s own stem cells thus slowing innovation and the […]
Stem Cell Research Helps Girl With Autism
A woman from New York has written an open letter to Obama saying that stem cell research using Adult Stem Cells has helped her daughter’s autism. Judy DiCorcia is reporting that her daughter, Lauren, a 10 year old girl with autism has improved significantly after the stem cell […]
MENLO PARK, Calif., August 18, 2009 – Geron Corporation announced that its IND (Investigational New Drug application) for GRNOPC1, a cell therapy for neurologically complete, subacute spinal cord injury, has been placed on clinical hold by the FDA pending the agency’s review of new nonclinical animal study data submitted by the company. A clinical hold is an order that the FDA issues to a sponsor to delay a proposed trial or to suspend an ongoing trial.
Since filing the IND, Geron has been undertaking studies to enable dose escalation of its spinal cord injury product, and has been investigating application